NEW YORK, June 8, 2017 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Shire plc ("Shire" or the "Company") (NASDAQ: SHPG). Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/shpg.
The investigation concerns whether Shire and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
On June 7, 2017, Shire revealed that it has stopped a U.S. study of Alpha-1 Antitrypsin (G1-ATT IV), its graft-versus-host disease treatment, and will hand over its Investigational New Drug application to Kamada Ltd. for additional testing. Following this news, Shire American Depositary Receipts dropped $3.09, or 1.77%, to close at $171.01 on June 7, 2017.
If you are aware of any facts relating to this investigation, or purchased Shire ADRs, you can assist this investigation by visiting the firm's site: www.bgandg.com/shpg. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | firstname.lastname@example.org
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-bronstein-gewirtz--grossman-llc-announces-investigation-of-shire-plc-shpg-300470960.html
SOURCE Bronstein, Gewirtz & Grossman, LLC